D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Bookmark and Share
Published: 8 Dec 2020
Views: 328
Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA

Prof Geyer speaks to ecancer about the updates in the D-ALBA study.

Initially he gives a brief overview of what this study was about and then moves on the recent updates regarding this study. He says that this study aims at exploring the activity of a frontline approach based on dasatinib plus steroids administration as induction treatment, followed by the infusion of blinatumomab, in adult Ph ALL.

He winds it up, by talking about what we know so far from the D-ALBA study and what we should be looking at in the future.